Cargando…

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer

BACKGROUND: Treatment strategies for patients with non‐small cell lung cancer (NSCLC) depend on various factors including physical condition, complications, tumor histology, and molecular profiling. Even if initial chemotherapy is efficacious, almost all patients develop treatment resistance. Invasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukui, Tomoya, Ishihara, Mikiko, Kasajima, Masashi, Hiyoshi, Yasuhiro, Nakahara, Yoshiro, Otani, Sakiko, Igawa, Satoshi, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397897/ https://www.ncbi.nlm.nih.gov/pubmed/30648806 http://dx.doi.org/10.1111/1759-7714.12964

Ejemplares similares

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019)

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2020)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2021)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
por: Ono, Taihei, et al.
Publicado: (2019)

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study
por: Sone, Hideyuki, et al.
Publicado: (2018)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Akazawa, Yuki, et al.
Publicado: (2023)

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
por: Igawa, Satoshi, et al.
Publicado: (2018)

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
por: Nakahara, Yoshiro, et al.
Publicado: (2018)

Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
por: Fukui, Tomoya, et al.
Publicado: (2016)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
por: Kasajima, Masashi, et al.
Publicado: (2023)

Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
por: Yagami, Yuri, et al.
Publicado: (2022)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
por: Igawa, Satoshi, et al.
Publicado: (2013)

Endobronchial involvement of mantle cell lymphoma: A case report
por: Katono, Ken, et al.
Publicado: (2016)

Successful Chemotherapy with Nab-Paclitaxel in a Heavily Treated Non-Small Cell Lung Cancer Patient: A Case Report
por: Ishihara, Mikiko, et al.
Publicado: (2014)

Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017
por: Nakahara, Yoshiro, et al.
Publicado: (2019)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
por: Fukui, Tomoya, et al.
Publicado: (2022)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Circulating tumor cells as a prognostic factor in patients with small cell lung cancer
por: IGAWA, SATOSHI, et al.
Publicado: (2014)

Comparison between quantitative computed tomography, scintigraphy, and anatomical methods for prediction of postoperative FEV(1) and DLCO: effects of chronic obstructive pulmonary disease status and resected lobes
por: Yokoba, Masanori, et al.
Publicado: (2020)

Rebiopsy rate after transperineal or transrectal prostate biopsy
por: Marenco Jimenez, Jose L., et al.
Publicado: (2021)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

The characteristics and spatial distributions of initially missed and rebiopsy-detected prostate cancers
por: You, Myung-Won, et al.
Publicado: (2016)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods
por: Zarogoulidis, Paul, et al.
Publicado: (2019)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
por: Matsuda, Asako, et al.
Publicado: (2019)

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments
por: Jekunen, Antti P.
Publicado: (2015)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
por: Rajamäki, Aino, et al.
Publicado: (2022)

Transrectal ultrasound-guided prostate rebiopsy: How many core sampling should be applied to which patient?
por: Amasyalı, Akın Soner, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6siu0upuilbbo2i7836c863dtc